A. Tuba Kendi

2.4k total citations · 1 hit paper
98 papers, 1.3k citations indexed

About

A. Tuba Kendi is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, A. Tuba Kendi has authored 98 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pulmonary and Respiratory Medicine, 43 papers in Radiology, Nuclear Medicine and Imaging and 28 papers in Oncology. Recurrent topics in A. Tuba Kendi's work include Prostate Cancer Treatment and Research (37 papers), Radiopharmaceutical Chemistry and Applications (35 papers) and Neuroendocrine Tumor Research Advances (17 papers). A. Tuba Kendi is often cited by papers focused on Prostate Cancer Treatment and Research (37 papers), Radiopharmaceutical Chemistry and Applications (35 papers) and Neuroendocrine Tumor Research Advances (17 papers). A. Tuba Kendi collaborates with scholars based in United States, Canada and Germany. A. Tuba Kendi's co-authors include Þorvarður R. Hálfdánarson, Oliver Sartor, Geoffrey B. Johnson, Albert Jang, Panithaya Chareonthaitawee, Saira Ajmal, M. Rizwan Sohail, Larry M. Baddour, Saira Farid and Maryam Mahmood and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

A. Tuba Kendi

88 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Theranostics and artificial intelligence: new frontiers in personalized medicine

2024 52 citations Gokce Belge Bilgin, Brian J. Burkett et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Tuba Kendi United States	20	456	433	392	308	293	98	1.3k
Claus C. Pieper Germany	22	545 1.2×	285 0.7×	342 0.9×	248 0.8×	645 2.2×	165	1.7k
Sebastian Lehner Germany	19	489 1.1×	284 0.7×	209 0.5×	239 0.8×	265 0.9×	64	1.1k
David A. Pattison Australia	21	453 1.0×	546 1.3×	334 0.9×	396 1.3×	290 1.0×	82	1.4k
Sophia Koukouraki Greece	16	324 0.7×	237 0.5×	255 0.7×	254 0.8×	436 1.5×	39	1.4k
Yuji Baba Japan	23	700 1.5×	343 0.8×	272 0.7×	344 1.1×	475 1.6×	89	1.9k
Frederic Carsten Schmeel Germany	23	461 1.0×	143 0.3×	292 0.7×	261 0.8×	236 0.8×	63	1.5k
Usman Ahmad United States	22	148 0.3×	521 1.2×	377 1.0×	194 0.6×	578 2.0×	101	1.5k
Éric Frampas France	22	458 1.0×	266 0.6×	283 0.7×	428 1.4×	423 1.4×	96	1.4k
Tamio Aburano Japan	23	453 1.0×	480 1.1×	318 0.8×	180 0.6×	506 1.7×	149	1.7k
Bennett B. Chin United States	23	845 1.9×	382 0.9×	178 0.5×	260 0.8×	449 1.5×	91	1.7k

Countries citing papers authored by A. Tuba Kendi

Since Specialization

Citations

This map shows the geographic impact of A. Tuba Kendi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Tuba Kendi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Tuba Kendi more than expected).

Fields of papers citing papers by A. Tuba Kendi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Tuba Kendi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Tuba Kendi. The network helps show where A. Tuba Kendi may publish in the future.

Co-authorship network of co-authors of A. Tuba Kendi

This figure shows the co-authorship network connecting the top 25 collaborators of A. Tuba Kendi. A scholar is included among the top collaborators of A. Tuba Kendi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Tuba Kendi. A. Tuba Kendi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Das, Arabinda, A. Tuba Kendi, & Sandhya Manohar. (2025). Peptide receptor radionuclide therapy: a new era of radiation nephropathy. Nephrology Dialysis Transplantation. 41(2). 220–232.

Childs, Daniel S., et al.. (2024). EARLY ADVERSE EVENTS, EMERGENCY ROOM VISITS AND HOSPITALIZATIONS AFTER PSMA BASED RLT: A RETROSPECTIVE ANALYSIS FROM REAL WORLD THERANOSTICS PRACTICE. Urologic Oncology Seminars and Original Investigations. 42. S12–S12.

Ahmed, Mohamed E., Ahmed Mahmoud, Irbaz Bin Riaz, et al.. (2024). Survival Patterns Based on First-site–specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same?. European Urology Open Science. 66. 38–45. 3 indexed citations

Parent, Ephraim E., Jason R. Young, Geoffrey B. Johnson, et al.. (2024). Assessment of hematological toxicity in patients with advanced neuroendocrine tumors and extensive/innumerable bone metastases undergoing lutetium-177 DOTATATE treatment.. Journal of Clinical Oncology. 42(3_suppl). 592–592.

Bilgin, Gokce Belge, Brian J. Burkett, Cem Bilgin, et al.. (2024). Neurologic Symptoms After¹⁷⁷Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience. Journal of Nuclear Medicine. 65(9). 1402–1408.

Calais, Jérémie, Michael J. Morris, A. Tuba Kendi, et al.. (2024). Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy. Journal of Nuclear Medicine. 65(11). 1666–1671. 5 indexed citations

Mahmoud, Ahmed, Mohamed E. Ahmed, Spyridon P. Basourakos, et al.. (2024). Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies. Cancers. 16(11). 2080–2080. 2 indexed citations

Hálfdánarson, Þorvarður R., et al.. (2023). Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy. Cancers. 15(19). 4836–4836. 3 indexed citations

Jang, Albert, A. Tuba Kendi, Geoffrey B. Johnson, Þorvarður R. Hálfdánarson, & Oliver Sartor. (2023). Targeted Alpha-Particle Therapy: A Review of Current Trials. International Journal of Molecular Sciences. 24(14). 11626–11626. 55 indexed citations

10.

Ahmed, Mohamed E., Raevti Bole, Jack R. Andrews, et al.. (2023). High-volume mCRPC is associated with decreased cancer specific survival in patients on second-generation hormone therapy in the post docetaxel setting.. Journal of Clinical Oncology. 41(6_suppl). 192–192. 1 indexed citations

11.

Ahmed, Mohamed E., Jack R. Andrews, Ahmed Mahmoud, et al.. (2023). Survival patterns based on site-specific visceral metastasis in patients with metastatic prostate cancer: Are outcomes of visceral metastases the same?. Journal of Clinical Oncology. 41(6_suppl). 269–269. 1 indexed citations

12.

Mahmoud, Ahmed, Mohamed E. Ahmed, A. Tuba Kendi, et al.. (2023). Low PSA radiographic disease progression on C11‐choline PET. SHILAP Revista de lepidopterología. 5(2). 319–324. 1 indexed citations

13.

Mahmoud, Ahmed, Daniel S. Childs, Mohamed E. Ahmed, et al.. (2023). Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis. The Prostate. 84(3). 237–244. 2 indexed citations

14.

Ahmed, Mohamed E., et al.. (2023). Prostate Cancer: Advances in Genetic Testing and Clinical Implications. SHILAP Revista de lepidopterología. 3(2). 91–103. 1 indexed citations

15.

Ahmed, Mohamed E., Ahmed Mahmoud, Raevti Bole, et al.. (2023). Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 27(2). 334–338. 1 indexed citations

16.

Mahmoud, Ahmed, et al.. (2022). Recent Advances in Prostate Cancer (PCa) Diagnostics. SHILAP Revista de lepidopterología. 2(2). 109–121. 2 indexed citations

17.

Panda, Ananya, Akash Sharma, Annie T. Packard, et al.. (2021). Twitter Use by Academic Nuclear Medicine Programs: Pilot Content Analysis Study. JMIR Formative Research. 5(11). e24448–e24448. 4 indexed citations

18.

Osman, Karim T., A. Tuba Kendi, & Daniel B. Maselli. (2021). Isolated angioedema of the bowel caused by aspirin. Clinical Journal of Gastroenterology. 14(4). 1096–1102.

19.

Starr, Jason S., Mohamad Bassam Sonbol, Timothy J. Hobday, et al.. (2020). <p>Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights</p>. OncoTargets and Therapy. Volume 13. 3545–3555. 26 indexed citations

20.

Lee, Ryan K., Judah Burns, Joshua Broder, et al.. (2020). ACR Appropriateness Criteria® Seizures and Epilepsy. Journal of the American College of Radiology. 17(5). S293–S304. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact